AU2004213752B2 - Methods and compositions for administering therapeutic and diagnostic agents - Google Patents

Methods and compositions for administering therapeutic and diagnostic agents Download PDF

Info

Publication number
AU2004213752B2
AU2004213752B2 AU2004213752A AU2004213752A AU2004213752B2 AU 2004213752 B2 AU2004213752 B2 AU 2004213752B2 AU 2004213752 A AU2004213752 A AU 2004213752A AU 2004213752 A AU2004213752 A AU 2004213752A AU 2004213752 B2 AU2004213752 B2 AU 2004213752B2
Authority
AU
Australia
Prior art keywords
binding
agent
antibody
targetable construct
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004213752A
Other languages
English (en)
Other versions
AU2004213752A1 (en
Inventor
Chien-Hsing Ken Chang
David M. Goldenberg
Hans J. Hansen
William Mcbride
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of AU2004213752A1 publication Critical patent/AU2004213752A1/en
Application granted granted Critical
Publication of AU2004213752B2 publication Critical patent/AU2004213752B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2004213752A 2003-01-31 2004-02-02 Methods and compositions for administering therapeutic and diagnostic agents Ceased AU2004213752B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44435703P 2003-01-31 2003-01-31
US60/444,357 2003-01-31
PCT/US2004/002768 WO2004074434A2 (en) 2003-01-31 2004-02-02 Methods and compositions for administering therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
AU2004213752A1 AU2004213752A1 (en) 2004-09-02
AU2004213752B2 true AU2004213752B2 (en) 2008-10-23

Family

ID=32908405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004213752A Ceased AU2004213752B2 (en) 2003-01-31 2004-02-02 Methods and compositions for administering therapeutic and diagnostic agents

Country Status (10)

Country Link
US (3) US7534431B2 (https=)
EP (1) EP1587550B1 (https=)
JP (1) JP4874090B2 (https=)
CN (1) CN1767860A (https=)
AT (1) ATE517638T1 (https=)
AU (1) AU2004213752B2 (https=)
CA (1) CA2514277C (https=)
IL (1) IL169896A (https=)
MX (1) MXPA05008222A (https=)
WO (1) WO2004074434A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405320B2 (en) * 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
CN1767860A (zh) * 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005207026A1 (en) * 2004-01-22 2005-08-04 Immunomedics, Inc. Folate conjugates and complexes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
GB0524987D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
AU2007211334A1 (en) * 2006-02-01 2007-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
BRPI0711586A2 (pt) * 2006-05-15 2011-11-16 Immunonomedics, Inc. método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2076257A4 (en) * 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
US8475763B2 (en) * 2008-10-09 2013-07-02 Actis, Ltd. Method of determining the course of treatment for a patient having adenocarcinoma
US8512728B2 (en) * 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
CN102666567B (zh) * 2009-12-04 2015-08-26 免疫医疗公司 用于蛋白质、肽和其它分子的改进的f-18标记的方法和组合物
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
EP2575848A4 (en) * 2010-05-29 2016-09-07 Univ Ben Gurion ENCAPSULATED CONJUGATES OF A CELL PENETRATING PEPTIDE FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2012112317A1 (en) * 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20130231583A1 (en) * 2012-03-02 2013-09-05 Donna Rekkerth Methods and Compositions for Injection Delivery
EP3984556B8 (en) 2012-06-14 2025-07-09 Microvention, Inc. Polymeric treatment compositions
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
AU2013331439B2 (en) 2012-10-15 2016-05-12 Microvention, Inc. Polymeric treatment compositions
JP6064601B2 (ja) 2013-01-09 2017-01-25 オムロンヘルスケア株式会社 超音波式吸入器用の薬液槽および薬液パック
WO2014111553A1 (de) * 2013-01-17 2014-07-24 Sit Soft Intelligent Therapeutics Gmbh & Co Kg Selektives zelltod-induzierendes binäres enzymsystem
CA2895284A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
JP6270264B2 (ja) * 2014-02-04 2018-01-31 株式会社ミツトヨ 情報処理装置、情報処理方法、プログラム、測定装置、及び測定方法
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10126298B2 (en) 2015-05-04 2018-11-13 Arman Nabatian Hydrogels containing embedded substrates for targeted binding of molecules
WO2016191481A1 (en) 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
US10368874B2 (en) 2016-08-26 2019-08-06 Microvention, Inc. Embolic compositions
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
WO2018085050A1 (en) * 2016-11-03 2018-05-11 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for imaging tissues and tumors
EP3375871A1 (en) 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2019074965A1 (en) * 2017-10-09 2019-04-18 Microvention, Inc. EMBOLIC RADIOACTIVE LIQUID
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CN112218683A (zh) * 2018-05-30 2021-01-12 睿谱外科系统股份有限公司 靠近关键结构的辐射外科手术神经调节
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030745A2 (en) * 1997-12-15 1999-06-24 Immunomedics, Inc. Dota-biotin derivatives
US20020006379A1 (en) * 1998-06-22 2002-01-17 Hansen Hans J. Production and use of novel peptide-based agents for use with bi-specific antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4150149A (en) 1976-11-29 1979-04-17 Professional Staff Association Of The Los Angeles County Harbor General Hospital Method and means for the early detection and diagnosis of certain types of cancers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1993021940A1 (en) 1992-05-06 1993-11-11 Immunomedics, Inc. Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
US5914312A (en) * 1992-06-09 1999-06-22 Neorx Corporation Pretargeting methods and compounds
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
US5846741A (en) 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
JPH09506106A (ja) * 1993-12-07 1997-06-17 ネオルクス コーポレーション プレターゲティング方法及び化合物
ES2251723T3 (es) * 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5965115A (en) 1997-11-05 1999-10-12 The Procter & Gamble Company Personal care compositions
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
WO1999066951A2 (en) 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1468097A4 (en) * 2001-12-26 2006-01-11 Immunomedics Inc PROCESS FOR GENERATING MULTI-QUALITY REAGENTS WITH MULTIPLE SPECIFICITY FROM V SB H / SB AND V SB L / SB DOMAINS
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
CA2478011C (en) * 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
WO2003074566A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP4083507B2 (ja) * 2002-08-28 2008-04-30 セイコーインスツル株式会社 半導体装置の製造方法
CN1767860A (zh) * 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
CA2529027C (en) * 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030745A2 (en) * 1997-12-15 1999-06-24 Immunomedics, Inc. Dota-biotin derivatives
US20020006379A1 (en) * 1998-06-22 2002-01-17 Hansen Hans J. Production and use of novel peptide-based agents for use with bi-specific antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Karacay, H. et al. Bioconjugate. Chem. 1997, vol. 8, pp. 585-594 *
Karacay, H. et al. Bioconjugate. Chem. 2002, vol. 13, pp. 1054-1070 *
Sharkey, R.M. et al. Can. Res. 15 01 2003, vol. 63, pp. 354-363 *

Also Published As

Publication number Publication date
EP1587550B1 (en) 2011-07-27
US7892547B2 (en) 2011-02-22
IL169896A (en) 2011-03-31
ATE517638T1 (de) 2011-08-15
WO2004074434A3 (en) 2005-03-17
CN1767860A (zh) 2006-05-03
JP2006518737A (ja) 2006-08-17
CA2514277A1 (en) 2004-09-02
US7534431B2 (en) 2009-05-19
MXPA05008222A (es) 2005-10-05
JP4874090B2 (ja) 2012-02-08
US20110117010A1 (en) 2011-05-19
EP1587550A2 (en) 2005-10-26
US20090238757A1 (en) 2009-09-24
AU2004213752A1 (en) 2004-09-02
US8097252B2 (en) 2012-01-17
IL169896A0 (en) 2007-07-04
US20040241158A1 (en) 2004-12-02
CA2514277C (en) 2015-01-20
WO2004074434A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
AU2004213752B2 (en) Methods and compositions for administering therapeutic and diagnostic agents
JP4113670B2 (ja) プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
JP4455322B2 (ja) 二重特異性抗体ならびにキャリアペプチドと活性薬剤を含むハプテン構築物を用いる薬物プレターゲッティング
US7943343B2 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
JP4937751B2 (ja) Ｄ−アミノ酸ペプチド
US20040018557A1 (en) Bispecific antibody point mutations for enhancing rate of clearance
JP2007528372A (ja) 多特異性抗体との使用のための治療および診断用コンジュゲート
US20030026764A1 (en) Polymeric delivery systems
KR20060118318A (ko) 치료 및 진단용 제제의 투여방법 및 투여용 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired